Navigation Links
deCODE Genetics Announces Full-year 2007 Financial Results
Date:3/12/2008

k and optimizing measures to prevent these diseases.

deCODE's growing list of tests include deCODE T2(TM), for assessing

inherited risk of type 2 diabetes; deCODE AF(TM), for assessing risk of

atrial fibrillation, a common precursor of stroke; deCODE MI(TM), a

test for a major genetic risk factor for early-onset heart attack as

well as abdominal aortic and intracranial aneurysms; deCODE ProCa(TM),

which detects several significant genetic risk variants for prostate

cancer; and we have recently completed work on a test for assessing

inherited risk of a major type of glaucoma.

-- deCODEme(TM). Bringing together deCODE's leadership in human genetics

and recent advances in genotyping technology, in November 2007 deCODE

launched the first personal genome analysis service: deCODEme(TM). The

service takes advantage of deCODE's leadership in human genetics and

its whole-genome genotyping capabilities. Through deCODEme(TM),

subscribers can put themselves in the context of the latest discoveries

in genetics, learning what their own DNA says about their ancestry,

certain physical traits, as well as whether they have genetic variants

that have been associated with higher or lower than average risk of a

range of common diseases. This information is continually updated as

new discoveries are made, and is presented in the subscriber's secure

individual web page.

-- Arterial thrombosis: DG041. DG041 is deCODE's novel, first-in-class

antagonist of the EP3 receptor for prostaglandins E2, being developed

as a next-generation oral anti-platelet therapy for preventing arterial

thrombosis without increasing bleeding time. In a Phase II clinical

trial and additional clinical pharmacology studies completed in 2007,

DG041 was shown to dramatically inhibit platelet
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. deCODE genetics Announces Third Quarter 2007 Financial Results
4. deCODE Launches deCODEme(TM)
5. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
6. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
7. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
9. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... presentation Sunday, May 17, 8:15 a.m. PDT - - ... p.m. PDT - - Conference call and webcast Tuesday, ... 14 InterMune, Inc. (Nasdaq: ITMN ) today ... presentations related to the company,s pulmonology programs will be presented ...
... substantially increased capacity, for continued growth,TORONTO, ... today robust double digit growth in sales, improved cash ... ended March 31, 2009. , In a news release ... 43% growth in the first half of 2009 coupled ...
... Dendreon Corporation today announced that Chief Executive Officer, ... Ernst & Young Entrepreneur Of The Year (R) ... Ernst & Young LLP, the awards program recognizes entrepreneurs ... financial performance and personal commitment to their businesses and ...
Cached Biology Technology:Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 3Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 4Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest 2
(Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
(Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
(Date:7/9/2014)... shows that some shark species may be able to cope ... with rising temperatures. , The Arctic today is best known ... always like that. Roughly 53 to 38 million years ago ... was more similar to a huge temperate forest with brackish ... of tapirs, hippo-like creatures, crocodiles and giant tortoises. Much of ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... on open water to date and other environmental factors led to ... Mexico, concludes a two-year scientific study released today. A team ... of Central Florida in Orlando published their findings in the journal ... years, scientists have been trying to figure out why there were ...
... PORTLAND, Ore. Researchers at Oregon Health & Science ... protein strongly linked to ALS (Amyotrophic Lateral Sclerosis) and ... different molecular pathways when genetically manipulated. The findings have ... diseases such as Alzheimer,s and Parkinson,s. ...
... For many of us, summer is a time synonymous with ... the United States. In 2011, corn was planted on ... nation continue its trend as the world,s largest exporter of ... desired production levels, most U.S. farmers apply synthetic nitrogen fertilizer ...
Cached Biology News:Study points to causes of high dolphin deaths in Gulf of Mexico 2Scientists develop new carbon accounting method to reduce farmers' use of nitrogen fertilizer 2Scientists develop new carbon accounting method to reduce farmers' use of nitrogen fertilizer 3
... (Ankyrin repeat and SOCS box-containing protein) This ... containing amino acids 75-93 and 348-368 of ... Catalog No. 40149) can be used as ... with mouse and rat Asb-2, based on ...
... Rabbit polyclonal to ErbB 2 - ... for all tested applications). ... AENPEYLGLDVPV conjugated to KLH, corresponding to ... Human c-ErbB2 Entrez ...
SHP-2 Antibody...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Biology Products: